Amicus Therapeutics Inc (FOLD) - Total Liabilities
Based on the latest financial reports, Amicus Therapeutics Inc (FOLD) has total liabilities worth $675.63 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Amicus Therapeutics Inc - Total Liabilities Trend (2003–2025)
This chart illustrates how Amicus Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See FOLD current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Amicus Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Amicus Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sabra Healthcare REIT Inc
NASDAQ:SBRA
|
USA | $2.80 Billion |
|
Fortune Brands Innovations Inc.
NYSE:FBIN
|
USA | $4.19 Billion |
|
CSN Mineração S.A
SA:CMIN3
|
Brazil | R$26.79 Billion |
|
LG Display Co Ltd
NYSE:LPL
|
USA | $19.52 Trillion |
|
Andon Health Co Ltd
SHE:002432
|
China | CN¥8.08 Billion |
|
CNO Financial Group Inc
NYSE:CNO
|
USA | $36.47 Billion |
|
JK Cement Limited
NSE:JKCEMENT
|
India | Rs114.10 Billion |
|
China Southern Power Grid Technology Co Ltd
SHG:688248
|
China | CN¥1.45 Billion |
Liability Composition Analysis (2003–2025)
This chart breaks down Amicus Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see FOLD company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.84 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.46 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.71 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Amicus Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Amicus Therapeutics Inc (2003–2025)
The table below shows the annual total liabilities of Amicus Therapeutics Inc from 2003 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $675.63 Million | +14.32% |
| 2024-12-31 | $590.99 Million | -4.33% |
| 2023-12-31 | $617.71 Million | +2.76% |
| 2022-12-31 | $601.12 Million | +0.56% |
| 2021-12-31 | $597.77 Million | -0.39% |
| 2020-12-31 | $600.14 Million | +60.56% |
| 2019-12-31 | $373.78 Million | -16.39% |
| 2018-12-31 | $447.04 Million | +63.05% |
| 2017-12-31 | $274.17 Million | -59.48% |
| 2016-12-31 | $676.69 Million | +20.72% |
| 2015-12-31 | $560.55 Million | +538.52% |
| 2014-12-31 | $87.79 Million | +7.31% |
| 2013-12-31 | $81.81 Million | +100.19% |
| 2012-12-31 | $40.87 Million | +1.65% |
| 2011-12-31 | $40.20 Million | -15.57% |
| 2010-12-31 | $47.62 Million | +251.76% |
| 2009-12-31 | $13.54 Million | -76.55% |
| 2008-12-31 | $57.73 Million | -9.51% |
| 2007-12-31 | $63.80 Million | -53.49% |
| 2006-12-31 | $137.16 Million | +112.65% |
| 2005-12-31 | $64.50 Million | +6895.65% |
| 2004-12-31 | $922.00K | -84.04% |
| 2003-12-31 | $5.78 Million | -- |
About Amicus Therapeutics Inc
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha … Read more